Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of relapsing multiple sclerosis (RMS) (McDonald Criteria 2010)~* Active disease~* Expanded disability status scale (EDSS) 0 - 5.5 (inclusive) at screening~Exclusion Criteria:~* Treatment with prior Anti-cluster of differentiate 20 (CD20) or other B cell directed treatment~* Treatment with the following therapies at any time prior to randomization: alemtuzumab, natalizumab, teriflunomide, leflunomide and Stem cell transplantation~* Diagnosed with primary progressive multiple sclerosis (PPMS)~* Pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Ublituximab + Oral Placebo (Type: EXPERIMENTAL): Participants received ublituximab intravenous (IV) infusion, 150 milligrams (mg) over 4 hours (h) on Day 1 followed by 450 mg over 1 h on Days 15, 168, 336 and 504 (Week 72) along with the oral placebo tablet, once daily (QD) from Day 1 up to the last day of Week 95.
- Teriflunomide + IV Placebo (Type: ACTIVE_COMPARATOR): Participants received teriflunomide 14 mg tablet, orally, QD from Day 1 up to the last day of Week 95 along with the placebo IV infusion on Days 1, 15, 168, 336 and 504 (Week 72).

Based on this trial design, predict the completion outcome and termination type (if applicable).